Searched for
MRNA TECHNOLOGY PATENTS
Moderna stocks: MRNA shares jump in US Stock market today after pharma giant surpasses Wall Street estimatesModerna had earlier posted a loss of $2.52 per share a year earlier, while analysts expected a loss of $3.96 per share.- US Stocks: Moderna rises on $2.25 billion settlement, clearing COVID vaccine patent dispute overhangModerna shares rose 9% on Wednesday after it settled a long-running legal battle over the technology that made its COVID-19 vaccine possibl...
- Emcure and its subsidiary Gennova settle legal dispute with HDT Bio over mRNA technologyEmcure Pharmaceuticals and its subsidiary Gennova have resolved all legal disputes with US-based HDT Bio Corp. The parties have entered int...
- GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technologyGlaxoSmithKline (GSK) has filed a lawsuit against Pfizer and BioNTech in Delaware federal court, alleging infringement of GSK's patents rel...
- Moderna open to supplying COVID vaccines to China, CEO says"We are open, we have the capacity" Bancel said about supplying its mRNA-based shots to the country, declining to say whether Moderna had s...
- Moderna sues Pfizer/BioNTech for patent infringement over COVID vaccineModerna alleges Pfizer/BioNTech, without permission, copied mRNA technology that Moderna had patented between 2010 and 2016, well before CO...
- View: The new TRIPS “waiver” solution is misguided18 months of negotiations have led to Members merely clarifying flexibilities that already exist and making some of these more burdensome t...
- Texas Lone Rangers vs Covid-19No praise is enough for Peter Hotez and Maria Elena Bottazzi, the Texans who might yet rescue the world. They have done what big government...
- View: Arriving at an equitable response to the pandemicThe Doha Declaration on TRIPS and public health clarified pre-existing flexibilities in the Agreement on Trade-Related Aspects of Intellect...
- How to fight climate change effectively? The failure of Covax has some powerful lessonsThe world will never be able to reach its climate goals if large emerging economies such as Brazil and India can't decarbonize just as fast...
- New protein-based Covid vaccine doesn't need cold storage: StudyThe research team at Boston Children's Hospital, US, noted that currently available Covid vaccines require cold storage and sophisticated m...
- Here’s why developing countries can make COVID-19 mRNA vaccinesDepending on wealthy nations to donate billions of doses is not working, public health experts say. The solution, many now believe, is for ...
- WHO-backed vaccine hub for Africa to copy Moderna COVID-19 shotModerna said last October it would not enforce patents related to its shot during the pandemic, raising hopes that other companies might be...
- A cure for cancer: After Covid vaccine, next mRNA miracle might be closer than you imagineThe new technology was not only lightning fast but also incredibly effective - mRNA Covid vaccines from both Moderna and Pfizer hit the bul...
- Government gears up for WTO patent battleAlthough India and South Africa’s joint proposal for a three-year TRIPS waiver for vaccines, drugs and equipment has been submitted, along ...
- Are patent waivers the best way to boost vaccine production? Arvind Panagariya decodesOpponents of the proposal have argued that the waiver will make no difference to the supply of vaccines. Patent-holders and pharmaceutical ...
- Vaccine maker BioNTech says no need to waive patentsUgur Sahin, the chief executive of BioNTech, rejected the U.S.-backed proposal to temporarily lift some intellectual property rights for va...
- Tech transfers, supply of materials must to scale up vaccine production: Bharat Biotech joint MDSpeaking at the EU-India Business Roundtable, Ella noted that more than patent relaxations, it is the partnerships and continuous supplies ...
- Drugmakers say Joe Biden misguided over vaccine patent waiverIf adopted by the World Trade Organisation, the proposal would invite new manufacturers that lack essential know-how and oversight from the...
- Vaccine tech transfer hard, next six months key in Covid fight, says leading vaccine makersOn Friday, senior executives from companies such as Moderna, GSK and Bharat Biotech addressed various issues on Covid vaccines, including e...
Load More
